[Skip to Content]
[Skip to Content Landing]
Original Investigation
January 2, 2020

Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades

Author Affiliations
  • 1Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
  • 2Division of General Pediatrics, Boston Children’s Hospital, Boston, Massachusetts
  • 3Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
  • 4Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
  • 5Department of Epidemiology/Cancer Control, St Jude Children’s Research Hospital, Memphis, Tennessee
  • 6Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston
  • 7Department of Medical Oncology, St Jude Children’s Research Hospital, Memphis, Tennessee
  • 8Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 9Department of Medicine, Duke University, Durham, North Carolina
  • 10Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts
JAMA Oncol. 2020;6(3):350-357. doi:10.1001/jamaoncol.2019.5582
Key Points

Question  Will the observed shortened life expectancy of adult survivors of childhood cancer lengthen over time given improvements in treatment and care?

Findings  Using a simulation model–based approach, this study estimates that children who received a diagnosis of and were treated for cancer in the 1990s will live longer into adulthood than those diagnosed in the 1970s. Despite improvements, these individuals remain at risk for a shortened lifespan owing to severe treatment-related late toxic effects.

Meaning  Evolving treatment approaches are projected to be associated with improved life expectancy after treatment for pediatric cancer, in particular among individuals who did not receive radiotherapy during childhood cancer treatment.

Abstract

Importance  Advances in childhood and adolescent cancer treatment have been associated with increased rates of cure during the past 3 decades; however, improvement in adult life expectancy for these individuals has not yet been reported.

Objectives  To project long-term survival and assess whether life expectancy will improve among adult survivors of childhood cancer who were treated in more recent decades.

Design, Setting, and Participants  A microsimulation model of competing mortality risks was developed using data from the Childhood Cancer Survivor Study on 5-year survivors of childhood cancer diagnosed between 1970 and 1999. The model included (1) late recurrence, (2) treatment-related late effects (health-related [subsequent cancers, cardiac events, pulmonary conditions, and other] and external causes), and (3) US background mortality rates.

Exposures  Treatment subgroups (no treatment or surgery only, chemotherapy alone, radiotherapy alone, and radiotherapy with chemotherapy) and individuals with acute lymphoblastic leukemia during childhood by era (1970-1979, 1980-1989, and 1990-1999).

Main Outcomes and Measures  Conditional life expectancy (defined as the number of years a 5-year survivor can expect to live), cumulative cause-specific mortality risk, and 10-year mortality risks conditional on attaining ages of 30, 40, 50, and 60 years.

Results  Among the hypothetical cohort of 5-year survivors of childhood cancer representative of the Childhood Cancer Survivor Study participants (44% female and 56% male; mean [SD] age at diagnosis, 7.3 [5.6] years), conditional life expectancy was 48.5 years (95% uncertainty interval [UI], 47.6-49.6 years) for 5-year survivors diagnosed in 1970-1979, 53.7 years (95% UI, 52.6-54.7 years) for those diagnosed in 1980-1989, and 57.1 years (95% UI, 55.9-58.1 years) for those diagnosed in 1990-1999. Compared with individuals without a history of cancer, these results represented a gap in life expectancy of 25% (95% UI, 24%-27%) (16.5 years [95% UI, 15.5-17.5 years]) for those diagnosed in 1970-1979, 19% (95% UI, 17%-20%) (12.3 years [95% UI, 11.3-13.4 years]) for those diagnosed in 1980-1989, and 14% (95% UI, 13%-16%) (9.2 years [95% UI, 8.3-10.4 years]) for those diagnosed in 1990-1999. During the 3 decades, the proportion of survivors treated with chemotherapy alone increased (from 18% in 1970-1979 to 54% in 1990-1999), and the life expectancy gap in this chemotherapy-alone group decreased from 11.0 years (95% UI, 9.0-13.1 years) to 6.0 years (95% UI, 4.5-7.6 years). In contrast, during the same time frame, only modest improvements in the gap in life expectancy were projected for survivors treated with radiotherapy (21.0 years [95% UI, 18.5-23.2 years] to 17.6 years [95% UI, 14.2-21.2 years]) or with radiotherapy and chemotherapy (17.9 years [95% UI, 16.7-19.2 years] to 14.8 years [95% UI, 13.1-16.7 years]). For the largest group of survivors by diagnosis—those with acute lymphoblastic leukemia—the gap in life expectancy decreased from 14.7 years (95% UI, 12.8-16.5 years) in 1970-1979 to 8.0 years (95% UI, 6.2-9.7 years).

Conclusions and Relevance  Evolving treatment approaches are projected to be associated with improved life expectancy after treatment for pediatric cancer, in particular among those who received chemotherapy alone for their childhood cancer diagnosis. Despite improvements, survivors remain at risk for shorter lifespans, especially when radiotherapy was included as part of their childhood cancer treatment.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    RE: Life expectancy of adult survivors of childhood cancer over 3 decades
    Tomoyuki Kawada, MD & PhD | Nippon Medical School
    Yeh et al. evaluated long-term survival among adult survivors of childhood cancer with special reference to treatment period (1). Compared with individuals without a history of cancer, a gap in life expectancy was 16.5 years in 1970s, 12.3 years in 1980s, and 9.2 years in 1990s. In addition, the life expectancy gap in this chemotherapy-alone group decreased from 11.0 years to 6.0 years. The authors concluded that improved life expectancy after treatment for pediatric cancer was observed in the past 3 decades. I have two concerns about their study.

    First, the authors described that the gap in life expectancy
    among survivors of childhood acute lymphoblastic leukemia decreased from 14.7 years in 1970s to 8.0 years in 1990s. They also described difference of the gap in life expectancy among treatment methods. Severity of childhood cancer might be closely related to treatment methods and might also be related to subsequent prognosis. Three decades contributed to advances in the treatment of childhood cancer and would relate to subsequent prognosis. The authors could present shortening of the life expectancy gap between patients with childhood cancer and individuals without a history of cancer in childhood, and the quality of life after incident of childhood cancer should also be evaluated as a further study.

    Second, Scott et al. examined the association between vigorous exercise and change in exercise with all-cause mortality in adult survivors of childhood cancer (2). At 15 years, the cumulative incidence of all-cause mortality was 11.7% for those who exercised 0 MET-h/wk, 8.6% for 3 to 6 MET-h/wk, 7.4% for 9 to 12 MET-h/wk, and 8.0% for 15 to 21 MET-h/wk. In addition, adjusted rate ratio (95% confidence interval) of increased exercise with mean MET-h/wk of 7.9 against low exercise over an 8-year period for all-cause mortality  was 0.60 (0.44-0.82). Continuing vigorous exercise can be achieved in subjects with good health condition, and linear dose-response relationship between the level of exercise and subsequent all-cause mortality could be recognized in subjects who exercised ≤12 MET-h/wk. Exercise might be closely related to other lifestyles, and long-term survival among adult survivors of childhood cancer should also be analyzed with variables of subsequent comorbid conditions.


    References
    1. Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol. 2020 Jan 2. doi: 10.1001/jamaoncol.2019.5582
    2. Scott JM, Li N, Liu Q, et al. Association of exercise with mortality in adult survivors of childhood cancer. JAMA Oncol. 2018;4(10):1352-1358. doi: 10.1001/jamaoncol.2018.2254
    CONFLICT OF INTEREST: None Reported
    READ MORE
    ×